Caris Diagnostics/Molecular Profiling Institute
This article was originally published in The Gray Sheet
Surgical pathology services provider Caris Diagnostics acquires molecular diagnostics firm Molecular Profiling Institute under a deal announced Dec. 6. Certified under the Clinical Laboratory Improvement Amendments, MPI is a specialty reference laboratory that provides prognostic testing services and resources for genomic and proteomic profiling to help guide physicians in the treatment of cancer and other diseases. The acquisition "demonstrates our commitment to deliver health improvement by advancing the commercialization of personalized medicine," states Caris' Chairman David Halbert
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.